{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:00:58Z","timestamp":1790089258715,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.rmed.2017.08.021","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T02:47:21Z","timestamp":1503542841000},"page":"184-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone"],"prefix":"10.1016","volume":"131","author":[{"given":"Kimiyuki","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4352-2450","authenticated-orcid":false,"given":"Masanori","family":"Shiratori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Nishikiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiki","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kuronuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2017.08.021_bib1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"ATS\/ERS\/JRS\/ALAT committee on idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1378\/chest.10-2572","article-title":"Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium","volume":"140","author":"Nathan","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.08.021_bib3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1164\/rccm.201403-0566OC","article-title":"Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences","volume":"190","author":"Natsuizaka","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.rmed.2017.08.021_bib5","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.08.021_bib7","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2017.08.021_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1586\/ers.11.52","article-title":"Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program","volume":"5","author":"Richeldi","year":"2011","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib9","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib10","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"ATS, ERS, JRS, ALAT. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"ATS\/ERS committee on idiopathic interstitial pneumonias. An official American thoracic society\/european respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.trsl.2012.01.012","article-title":"Peripheral blood biomarkers in idiopathic pulmonary fibrosis","volume":"159","author":"Vij","year":"2012","journal-title":"Transl. Res."},{"key":"10.1016\/j.rmed.2017.08.021_bib13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1164\/ajrccm.162.3.9910080","article-title":"Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent","volume":"162","author":"Takahashi","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1183\/09031936.02.00081102","article-title":"Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis","volume":"19","author":"Greene","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.08.021_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1440-1843.2006.00809.x","article-title":"Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D","volume":"11","author":"Takahashi","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.rmed.2017.08.021_bib16","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1378\/chest.08-2209","article-title":"Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis","volume":"135","author":"Kinder","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.08.021_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1440-1843.2006.00834.x","article-title":"Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis","volume":"11","author":"Yokoyama","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.rmed.2017.08.021_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1164\/ajrccm.165.3.2107134","article-title":"Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases","volume":"165","author":"Ohnishi","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A\u00a0multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib21","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference","volume":"184","author":"Du Bois","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/thoraxjnl-2011-201184","article-title":"Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis","volume":"67","author":"Richeldi","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2017.08.021_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1378\/chest.14-2817","article-title":"Sensitivity analyses of the change in FVC in a phase 3 trial of pirfenidone for idiopathic pulmonary fibrosis","volume":"148","author":"Lederer","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.08.021_bib24","first-page":"S17","article-title":"Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis","volume":"23","author":"Fisher","year":"2017","journal-title":"J.\u00a0Manag. Care Spec. Pharm."},{"key":"10.1016\/j.rmed.2017.08.021_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1465-9921-12-143","article-title":"Pirfenidone Clinical Study Group in Japan. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment","volume":"12","author":"Azuma","year":"2011","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2017.08.021_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.resinv.2013.09.002","article-title":"Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis","volume":"52","author":"Arai","year":"2014","journal-title":"Respir. Investig."},{"key":"10.1016\/j.rmed.2017.08.021_bib27","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2169\/internalmedicine.52.8498","article-title":"Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis","volume":"52","author":"Sakamoto","year":"2013","journal-title":"Intern. Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib28","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.rmed.2015.04.010","article-title":"Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study","volume":"109","author":"Harari","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1183\/13993003.01966-2015","article-title":"Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function","volume":"48","author":"Albera","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.08.021_bib30","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1177\/34.9.2426341","article-title":"Immunocytochemical localization of the major surfactant apoproteins in type II cells, Clara cells, and alveolar macrophages of rat lung","volume":"34","author":"Walker","year":"1986","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.rmed.2017.08.021_bib31","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1177\/40.10.1527377","article-title":"Immunocytochemical localization of surfactant protein D (SP-D) in type II cells, Clara cells, and alveolar macrophages of rat lung","volume":"40","author":"Voorhout","year":"1992","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.rmed.2017.08.021_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2174\/138161206775474387","article-title":"Pulmonary Surfactant Proteins A and D: Innate Immune Functions and biomarkers for lung diseases","volume":"12","author":"Takahashi","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.rmed.2017.08.021_bib33","article-title":"Diverse functions of pulmonary collectins in host defense of the lung","volume":"2012","author":"Ariki","year":"2012","journal-title":"J.\u00a0Biomed. Biotechnol."},{"key":"10.1016\/j.rmed.2017.08.021_bib34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-2466-14-196","article-title":"Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis","volume":"14","author":"Nishikiori","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib35","first-page":"224","article-title":"Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease","volume":"33","author":"Doubkov\u00e1","year":"2016","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"10.1016\/j.rmed.2017.08.021_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.rmed.2009.08.011","article-title":"Serum KL-6 in fibrotic NSIP: correlations with physiologic and radiologic parameters","volume":"104","author":"Sakamoto","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.08.021_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1148\/radiology.189.3.8234692","article-title":"Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation","volume":"189","author":"Remy-Jardin","year":"1993","journal-title":"Radiology"},{"key":"10.1016\/j.rmed.2017.08.021_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1148\/radiology.188.1.8511299","article-title":"Parenchymal opacification in chronic infiltrative lung diseases: CT-pathologic correlation","volume":"188","author":"Leung","year":"1993","journal-title":"Radiology"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117303013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117303013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:39:18Z","timestamp":1760614758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611117303013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":38,"alternative-id":["S0954611117303013"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2017.08.021","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2017.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}